Biohaven Pharmaceutical Holding Company Ltd.
BHVNDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
BHVN Earnings Report
EPS Est: $-0.77 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
BHV-7000
Bipolar Disorder
Taldefgrobep Alfa
Obesity
BHV-8000
Parkinson Disease
Verdiperstat
Multiple System Atrophy
troriluzole
Spinocerebellar Ataxias
BHV-1510
Solid Tumor
BHV-2100
Migraine
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BHV-7000 | Phase 3 | Bipolar Disorder | - | - |
Taldefgrobep Alfa | Phase 3 | Obesity | - | - |
BHV-8000 | Phase 3 | Parkinson Disease | - | - |
Verdiperstat | Phase 3 | Multiple System Atrophy | - | - |
troriluzole | Phase 3 | Spinocerebellar Ataxias | - | - |
BHV-1510 | Phase 2 | Solid Tumor | - | - |
BHV-2100 | Phase 2 | Migraine | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Biohaven Pharmaceutical Holding Company Ltd.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) pipeline across Phase 3, Phase 2. Its lead program is BHV-7000 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biohaven Pharmaceutical Holding Company Ltd.'s next FDA catalyst?→
Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BHVN biotech catalysts?→
Add BHVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biohaven Pharmaceutical Holding Company Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.